Robin Davison has been a consultant specialising in business analysis and equity capital market strategies in biotech companies for the past five years. Prior to this was an investment analyst specialising in biotech for over 15 years, most recently as head of the healthcare research team at Edison Investment Research, where he managed a team of 12 analysts covering more than 100 biotech, diagnostic and med-tech companies listed in the US, Europe, Canada, Australia and Israel. Prior to joining Edison, Robin was an investment analyst at Durlacher, a co-founder of a biotech investment web newsletter and editor of Scrip World Pharmaceutical News, a leading industry publication. Mr Davison is still an occasional commentator for biotech industry publications.
Sorry, there is no news by Robin Davison